Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01814-18. doi: 10.1128/AAC.01814-18. Print 2019 Apr.

2.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02569-17. doi: 10.1128/AAC.02569-17. Print 2018 Jul.

3.

In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.

Karlowsky JA, Hackel MA, Bouchillon SK, Alder J, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Oct;89(2):151-157. doi: 10.1016/j.diagmicrobio.2017.07.001. Epub 2017 Jul 8.

PMID:
28793964
4.

In vitro activity of tigecycline against molecularly characterised strains of Enterobacteriaceae isolated from phase 3 clinical trials and the Tigecycline Evaluation and Surveillance Trial (TEST).

Biedenbach DJ, Hackel MA, Quintana A, Wible M, Dowzicky MJ, McGovern PC, Bouchillon SK.

J Glob Antimicrob Resist. 2015 Dec;3(4):311-312. doi: 10.1016/j.jgar.2015.09.004. Epub 2015 Oct 22. No abstract available.

PMID:
27842883
5.

In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.

Biedenbach DJ, Bouchillon SK, Johnson B, Alder J, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2016 Dec;35(12):1933-1939. Epub 2016 Sep 27.

PMID:
27677280
6.

In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF.

Diagn Microbiol Infect Dis. 2016 Oct;86(2):194-9. doi: 10.1016/j.diagmicrobio.2016.07.012. Epub 2016 Jul 14.

PMID:
27461798
7.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.

Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4677-83. doi: 10.1128/AAC.02841-15. Print 2016 Aug.

8.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500. doi: 10.1128/AAC.00107-16. Print 2016 Aug.

9.

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. doi: 10.1128/AAC.02820-15.

10.

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y.

J Antimicrob Chemother. 2016 Mar;71(3):670-7. doi: 10.1093/jac/dkv402. Epub 2015 Dec 7.

PMID:
26645269
11.

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.

Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1067-78. doi: 10.1128/AAC.02379-15. Print 2016 Feb.

12.

In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF.

J Antimicrob Chemother. 2016 Jan;71(1):162-9. doi: 10.1093/jac/dkv311. Epub 2015 Oct 26.

PMID:
26503667
13.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):343-7. doi: 10.1128/AAC.01867-15. Print 2016 Jan.

14.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Hoban DJ, Reiszner E, Lahiri SD, Alm RA, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Dec;59(12):7873-7. doi: 10.1128/AAC.01833-15. Epub 2015 Sep 28.

15.

In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11.

16.

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.

Hoban DJ, Reinert RR, Bouchillon SK, Dowzicky MJ.

Ann Clin Microbiol Antimicrob. 2015 May 10;14:27. doi: 10.1186/s12941-015-0085-1.

17.

Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends.

Kazmierczak KM, Lob SH, Hoban DJ, Hackel MA, Badal RE, Bouchillon SK.

Diagn Microbiol Infect Dis. 2015 Jul;82(3):209-14. doi: 10.1016/j.diagmicrobio.2015.03.025. Epub 2015 Apr 9.

PMID:
25956930
18.

Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.

Hackel MA, Badal RE, Bouchillon SK, Biedenbach DJ, Hoban DJ.

Surg Infect (Larchmt). 2015 Jun;16(3):298-304. doi: 10.1089/sur.2014.060. Epub 2015 Apr 20.

PMID:
25894976
19.

Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013.

Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF.

Antimicrob Agents Chemother. 2015;59(6):3606-10. doi: 10.1128/AAC.05186-14. Epub 2015 Mar 23.

20.

In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012.

Renteria MI, Biedenbach DJ, Bouchillon SK, Hoban DJ, Raghubir N, Sajben P.

J Glob Antimicrob Resist. 2014 Sep;2(3):179-182. doi: 10.1016/j.jgar.2014.03.002. Epub 2014 Mar 26.

PMID:
27873726
21.

Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).

Biedenbach DJ, Bouchillon SK, Hoban DJ, Hackel M, Phuong DM, Nga TT, Phuong NT, Phuong TT, Badal RE.

Diagn Microbiol Infect Dis. 2014 Aug;79(4):463-7. doi: 10.1016/j.diagmicrobio.2014.05.009. Epub 2014 May 17.

PMID:
24923210
22.

Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study.

Biedenbach DJ, Bouchillon SK, Johnson SA, Hoban DJ, Hackel M.

Clin Ther. 2014 Jun 1;36(6):953-60. doi: 10.1016/j.clinthera.2014.04.003. Epub 2014 May 15.

PMID:
24835558
23.

In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.

Renteria MI, Biedenbach DJ, Bouchillon SK, Hoban DJ, Raghubir N, Sajben P, Mokaddas E.

Diagn Microbiol Infect Dis. 2014 May;79(1):54-9. doi: 10.1016/j.diagmicrobio.2014.01.017. Epub 2014 Jan 30.

PMID:
24582580
24.

Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011.

Hawser S, Hoban DJ, Badal RE, Bouchillon SK, Biedenbach D, Hackel M, Morrissey I.

J Chemother. 2015 Feb;27(2):67-73. doi: 10.1179/1973947814Y.0000000164. Epub 2014 Feb 18.

PMID:
24548089
25.

Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.

Morrissey I, Bouchillon SK, Hackel M, Biedenbach DJ, Hawser S, Hoban D, Badal RE.

J Med Microbiol. 2014 Apr;63(Pt 4):556-61. doi: 10.1099/jmm.0.068981-0. Epub 2014 Jan 29.

PMID:
24478449
26.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA.

J Infect. 2014 Jan;68(1):71-6. doi: 10.1016/j.jinf.2013.09.001. Epub 2013 Sep 7.

PMID:
24016768
28.
29.

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

Lob SH, Badal RE, Bouchillon SK, Hawser SP, Hackel MA, Hoban DJ.

Surg Infect (Larchmt). 2013 Apr;14(2):203-8. doi: 10.1089/sur.2012.034. Epub 2013 Mar 29.

PMID:
23540793
30.

Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Biedenbach DJ, Cantón R, Paterson DL.

Int J Antimicrob Agents. 2013 Mar;41(3):224-8. doi: 10.1016/j.ijantimicag.2012.10.014. Epub 2013 Jan 8.

PMID:
23305657
31.

Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hackel MA, Lascols CA, Villegas MV, Rossi F.

J Chemother. 2012 Feb;24(1):6-11. doi: 10.1179/1120009X12Z.0000000003.

PMID:
22546718
32.

Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.

Hawser SP, Bouchillon SK, Hackel M, Chen M, Kim EC.

Int J Antimicrob Agents. 2012 Jun;39(6):490-5. doi: 10.1016/j.ijantimicag.2012.02.018. Epub 2012 Apr 23.

PMID:
22534507
33.

Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world.

Lascols C, Hackel M, Hujer AM, Marshall SH, Bouchillon SK, Hoban DJ, Hawser SP, Badal RE, Bonomo RA.

J Clin Microbiol. 2012 May;50(5):1632-9. doi: 10.1128/JCM.06115-11. Epub 2012 Feb 8.

34.
35.

Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates.

Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, Woodford N, Livermore DM.

Antimicrob Agents Chemother. 2011 Aug;55(8):3917-21. doi: 10.1128/AAC.00070-11. Epub 2011 Jun 13.

36.

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).

Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, Cantón R.

Clin Microbiol Infect. 2012 Mar;18(3):253-9. doi: 10.1111/j.1469-0691.2011.03550.x. Epub 2011 Jun 2.

37.

Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.

Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, Paterson DL.

J Infect. 2011 Apr;62(4):280-91. doi: 10.1016/j.jinf.2011.02.009. Epub 2011 Mar 5.

PMID:
21382411
38.

Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.

Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T.

Int J Antimicrob Agents. 2011 Mar;37(3):219-24. doi: 10.1016/j.ijantimicag.2010.10.029. Epub 2011 Jan 15.

PMID:
21239146
39.

Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, Paterson DL; 2008 Asia–Pacific SMART Group.

Int J Antimicrob Agents. 2010 Nov;36(5):408-14. doi: 10.1016/j.ijantimicag.2010.07.002. Epub 2010 Aug 21.

PMID:
20728316
41.

Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR.

Int J Antimicrob Agents. 2010 Sep;36(3):293-4. doi: 10.1016/j.ijantimicag.2010.05.012. Epub 2010 Jul 3. No abstract available.

PMID:
20598511
42.

Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ; SMART India Working Group.

J Med Microbiol. 2010 Sep;59(Pt 9):1050-4. doi: 10.1099/jmm.0.020784-0. Epub 2010 Jun 10.

PMID:
20538892
43.

Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J.

Antimicrob Agents Chemother. 2010 Jul;54(7):3031-4. doi: 10.1128/AAC.01808-09. Epub 2010 May 10.

45.

In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study.

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE.

Int J Antimicrob Agents. 2009 Dec;34(6):585-8. doi: 10.1016/j.ijantimicag.2009.07.013. Epub 2009 Sep 11.

PMID:
19748234
46.

Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007.

Hoban DJ, Bouchillon SK, Hawser SP, Badal RE.

Diagn Microbiol Infect Dis. 2010 Jan;66(1):78-86. doi: 10.1016/j.diagmicrobio.2009.06.009. Epub 2009 Sep 5.

PMID:
19733993
47.

Klebsiellapneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece.

Hawser SP, Bouchillon SK, Hoban DJ, Hackel M, Johnson JL, Badal RE.

Int J Antimicrob Agents. 2009 Oct;34(4):384-5. doi: 10.1016/j.ijantimicag.2009.05.010. Epub 2009 Jun 27. No abstract available.

PMID:
19560904
48.

Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL.

Antimicrob Agents Chemother. 2009 Aug;53(8):3280-4. doi: 10.1128/AAC.00426-09. Epub 2009 Jun 8.

49.

Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).

Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ.

Int J Antimicrob Agents. 2009 Feb;33(2):130-6. doi: 10.1016/j.ijantimicag.2008.07.031. Epub 2008 Nov 7.

PMID:
18995992

Supplemental Content

Loading ...
Support Center